XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2024

Fair Value Measurements

Schedule of financial assets and liabilities measured at fair value on a recurring basis

The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):


		Fair Value Measurements as of September 30, 2024 Using:
		Quoted Prices in			Significant Other			Significant
		Active Markets for			Observable			Unobservable
		Identical Assets			Inputs			Inputs
		(Level 1)			(Level 2)			(Level 3)			Total
Assets:
Cash equivalents:
Money market funds		$	112,895		$	—		$	—		$	112,895
U.S. treasury bills			25,137			—			—			25,137
Total cash equivalents			138,032			—			—			138,032
Exarafenib milestone asset (Note 4)			—			—			3,125			3,125
Equity securities			785			—			—			785
Total financial assets		$	138,817		$	—		$	3,125		$	141,942
Liabilities:
Exarafenib milestone contingent consideration (Note 4)		$	—		$	—		$	3,125		$	3,125
Contingent consideration under RPAs, AAAs, and CPPAs, measured at fair value			—			—			—			—
Total financial liabilities		$	—		$	—		$	3,125		$	3,125


		Fair Value Measurements as of December 31, 2023 Using:
		Quoted Prices in			Significant Other			Significant
		Active Markets for			Observable			Unobservable
		Identical Assets			Inputs			Inputs
		(Level 1)			(Level 2)			(Level 3)			Total
Assets:
Cash equivalents:
Money market funds		$	28,352		$	—		$	—		$	28,352
Total cash equivalents			28,352			—			—			28,352
Equity securities			161			—			—			161
Total financial assets		$	28,513		$	—		$	—		$	28,513
Liabilities:
Contingent consideration under RPAs, AAAs, and CPPAs, measured at fair value		$	—		$	—		$	1,000		$	1,000